HealthDay News — Adjusted one-year mortality is similar for individuals undergoing transcatheter aortic valve replacement (TAVR) for on-label or off-label indications, according to a study published online June 21 in JAMA Cardiology.

Ravi S. Hira, MD, from the University of Washington in Seattle, and colleagues examined patterns and adverse outcomes of off-label use of TAVR, defined as TAVR in patients with known bicuspid valve, moderate aortic stenosis, severe mitral regurgitation, severe aortic regurgitation, or subaortic stenosis, in U.S. clinical practice. 

Related Articles

Off-label TAVR was used in 2,272 (9.5%) of the 23,847 patients in the study. The researchers found that patients receiving off-label TAVR had higher in-hospital mortality (6.3 versus 4.7%; P<0.001), 30-day mortality (8.5 versus 6.1%; P<0.001), and one-year mortality (25.6 versus 22.1%; P=0.001), compared to those receiving on-label TAVR. The off-label group had higher adjusted 30-day mortality (hazard ratio, 1.27; 95% confidence interval, 1.04 to 1.55; P=0.02), while adjusted one-year mortality was similar between the groups (hazard ratio, 1.11; 95% confidence interval, 0.98 to 1.25; P=0.11). Per hospital, the median rate of off-label TAVR use was 6.8%, with increased 30-day adverse cardiovascular events for hospitals in the highest tertile of off-label use versus the lowest tertile.

“These results reinforce the need for additional research on the efficacy of off-label TAVR use,” the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text
Editorial 1 (subscription or payment may be required)
Editorial 2 (subscription or payment may be required)